Supplier News Breaks Archives
Impax names Global Pharmaceutical president
September 7th, 2011
HAYWARD, Calif. – Carole Ben-Maimon has been appointed president of Global Pharmaceuticals, the generic pharmaceuticals division of Impax Laboratories Inc.
Impax said Tuesday that in the role, Dr. Ben-Maimon will be responsible for expanding Impax's generic drug business by growing capability in the U.S. market while driving global opportunities through partnerships and exploring M&A opportunities. She reports to Larry Hsu, president and chief executive officer of Impax.
"I am delighted to have the opportunity to devote my talents and experience to help the generics business grow. Impax has already distinguished itself with technological innovation, and I believe we can capitalize on the rare capability even further through careful product selection and strategic investments and partnerships," Ben-Maimon commented.
An M.D., Ben-Maimon comes to Impax with a broad base of executive experience in the pharmaceutical industry. Most recently, she was senior vice president of corporate strategy, consulting to the president, chief executive officer and investors at Qualitest Pharmaceuticals Inc. Before that, she held executive positions with Barr Pharmaceuticals, including president and chief operating officer of Duramed Research (formerly Barr Research), and with Teva Pharmaceuticals USA, where she was senior vice president of science and public policy. From 1996 to 2000, she served as senior vice president, research and development at Teva.
She has also served as president and chief executive officer of Alita Pharmaceuticals Inc., a company that she founded. She was chairman of the board of the Generic Pharmaceutical Association from 2000 to 2003.
"We are very pleased that Carole joins Impax and will be leading our generics division," Hsu said in a statement. "She is an accomplished executive with extensive pharmaceutical leadership experience. Her addition further enhances our management team and will be a key contributor in growing our generics business."